NASOPHARYNGEAL CANCINOMA (NPC)

This study aims to find the best initial chemotherapy combination to use with an immunotherapy drug (Toripalimab) for people with locally advanced nasopharyngeal cancer (a type of throat cancer). It will enroll 243 participants to compare three different drug combinations, all fo…

This study is testing two different combinations of advanced radiation therapy for people newly diagnosed with nasopharyngeal cancer. It aims to see if a newer type of radiation (proton therapy) combined with carbon ion therapy works as well as the standard radiation (photon ther…

This study is testing if adding a low dose of radiation to the liver, along with standard chemotherapy and immunotherapy, can better control cancer that has spread from the nasopharynx (upper throat) to the liver. It is for adults with advanced nasopharyngeal carcinoma who have n…

This study is testing if using a lower dose of radiation to treat certain areas around a throat cancer tumor is just as effective at controlling the cancer as the standard higher dose. It aims to see if the lower dose can provide the same survival benefits while causing fewer sid…

This study is testing whether targeted radiation treatment alone can effectively control early-stage nasopharyngeal cancer in patients without high-risk features. Researchers want to see if this approach can work without adding chemotherapy, potentially reducing treatment side ef…

This large Phase 3 trial is testing a personalized treatment strategy for advanced nasopharyngeal cancer. After initial chemo-immunotherapy, patients are split into two groups based on a blood test for EBV-DNA. Low-risk patients receive less intensive treatment (radiation only) t…

This study is testing if adding a traditional Chinese herbal liquid called Houyanqing to standard care works better than standard care alone at preventing and reducing severe mouth sores in people receiving radiation therapy for nasopharyngeal cancer. It will involve 244 patients…

This study aims to find biological markers that can predict how well patients with nasopharyngeal cancer (NPC) respond to radiotherapy and what side effects they might experience. It will follow 500 patients with early to mid-stage NPC who are receiving either proton or photon ra…